<DOC>
	<DOCNO>NCT02791594</DOCNO>
	<brief_summary>Up 35 adult patient metastatic melanoma enrol study target enrollment 30 evaluable subject complete baseline approximately 3 week FDG PET/CT scan , may also complete FDG PET/CT 10 week pembrolizumab therapy . Subjects may also part Penn Melanoma Tissue Collection Program ask one additional tumor biopsy one additional blood draw purpose image study . Subjects eligible image protocol undergo baseline FDG PET/CT scan part clinical restaging prior start new therapy . A research FDG PET/CT take place approximately 3 week post-therapy 3rd FDG PET/CT scan do 10 week start pembrolizumab , scan may do clinical scan evaluation response restaging therapy , however , order clinical scan do research scan . Changes FDG uptake correlate blood tissue result patient 's medical record data collect part Penn Melanoma Tissue Collection Program long term outcome include progression free overall survival .</brief_summary>
	<brief_title>Imaging FDG Flare Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>The subject must inform investigational nature study provide write informed consent accordance institutional federal guideline prior studyspecific procedure . The subject must â‰¥ 18 year age day sign informed consent . The subject must biopsy proven clinically document advanced stage metastatic melanoma . The subject must measurable disease ( per RECIST 1.1 ) see CT , MRI , FDG PET/CT . The subject must recommend start pembrolizumab . Females pregnant breastfeeding time screen eligible study . Female participant childbearing potential urine pregnancy test time screen visit . Subject able tolerate imaging procedure opinion investigator treat physician . Subject history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . Subject receive prior therapy antiPD1 , antiPDL1 , antiPDL2 agent assess medical record review and/or selfreported . Subject known history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) determine medical record review . Subject diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . Subject know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) determine medical record review . Subject know active central nervous system metastases and/or carcinomatous meningitis . Note : Subjects previously treat brain metastasis eligible participate provide stable ( without evidence progression image least four week prior receive pembrolizumab neurologic symptom return baseline ) , evidence new enlarge brain metastasis , use steroid least 7 day prior trial treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>